NASDAQ: TWST · Life Sciences · 17 alerts · CIK 1581280
Share price
$105.04Close, Nov 16
Market cap
$7.16B
Shares outstanding
68.18MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Twist Bioscience Corp filings on SEC EDGAR ↗
Twist Bioscience reported net proceeds of approximately $327.7 million from an August 2026 public offering and $97.1 million from an at-the-market program. Despite these capital raises, the company anticipates continued net losses and negative free cash flows for the near future while expanding international operations, which accounted for 41% of revenue in fiscal 2026.
Twist Bioscience reported record fiscal 2026 revenue of $459.4 million, a 22% increase year-over-year, driven by strong growth in DNA Synthesis and NGS Applications. The company achieved positive adjusted EBITDA in the fourth quarter and improved its annual gross margin to 52.4%. Management issued fiscal 2027 revenue guidance of $550 million to $560 million, representing approximately 21% growth at the midpoint.
Term
FY2026
“Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin and positive adjusted EBITDA in the fourth quarter, all while continuing to broaden our capabilities and strengthen our balance sheet.”
Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience
“We enter fiscal 2027 with a stronger business and the capital to invest in our next phase of growth. AI is expanding what scientists can design, and personalized medicine is increasing the demand for unique molecules. Both play directly to our strength of customization at scale.”
Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience